Harrow (NASDAQ:HROW) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Harrow (NASDAQ:HROW) released its quarterly earnings results on Thursday. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%.

Harrow Stock Up 0.8 %

Shares of HROW stock traded up $0.22 during trading on Thursday, reaching $27.87. The company’s stock had a trading volume of 394,681 shares, compared to its average volume of 489,222. The business has a fifty day moving average price of $29.17 and a 200-day moving average price of $38.18. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow has a one year low of $9.86 and a one year high of $59.23. The company has a market cap of $992.59 million, a price-to-earnings ratio of -29.65 and a beta of 0.69.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Harrow in a research report on Tuesday, March 18th. B. Riley decreased their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.